10-K: BiomX Inc. Details Securities Registered Under Exchange Act

BiomX Inc. outlines the terms of its registered securities, including common stock, units, and warrants, all listed on the NYSE American Stock Market.

Summary

• BiomX Inc. has registered three classes of securities under the Securities Exchange Act of 1934: common stock, units (each consisting of one share of common stock and one warrant), and warrants.
• The company's authorized capital stock includes 120,000,000 shares of common stock and 1,000,000 shares of preferred stock.
• Common stockholders are entitled to one vote per share and have no conversion, preemptive, or sinking fund rights.
• The company has not paid any cash dividends on its common stock to date and does not intend to in the foreseeable future.
• There are 256,888 Series X Non-Voting Convertible Preferred Stock outstanding, which are convertible into 1,000 shares of common stock each, subject to certain ownership limitations.
• Warrants allow holders to purchase one-half of a share of common stock at $11.50 per whole share, exercisable from December 18, 2019, and expiring on October 28, 2024.
• The company may redeem warrants for $0.01 per warrant under specific conditions, including a common stock price of $16.00 or more for 20 trading days within a 30-day period.
• The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances, such as stock dividends or mergers.
• The company is subject to Section 203 of the Delaware General Corporation Law, which regulates corporate takeovers.
• Special meetings of stockholders can only be called by a majority vote of the Board of Directors or by the chief executive officer.
• The Board of Directors is divided into three classes, with directors serving three-year terms.
• Stockholders must provide timely written notice to bring business before annual meetings or nominate directors.

Sentiment

Score: 6

Explanation: The document is neutral in tone, providing factual information about the company's securities. There are no explicit positive or negative statements, but the lack of dividends and the presence of anti-takeover provisions could be seen as slightly negative by some investors.

Positives

• The company's securities are listed on the NYSE American Stock Market, providing liquidity for investors.
• The warrants offer a potential upside for investors if the stock price increases above the exercise price.
• The company has the ability to redeem warrants, which could potentially reduce dilution.
• The company has the ability to issue preferred stock, which could be used for strategic purposes.

Negatives

• The company has not paid any cash dividends and does not plan to in the foreseeable future, which may not appeal to income-seeking investors.
• The warrants expire on October 28, 2024, which may limit their value if the stock price does not reach the redemption threshold.
• The company is subject to anti-takeover provisions, which may discourage potential acquirers.
• The company has the ability to issue preferred stock with terms that could adversely affect common stockholders.

Risks

• The company has not paid any cash dividends and does not plan to in the foreseeable future, which may not appeal to income-seeking investors.
• The warrants expire on October 28, 2024, which may limit their value if the stock price does not reach the redemption threshold.
• The company is subject to anti-takeover provisions, which may discourage potential acquirers.
• The company has the ability to issue preferred stock with terms that could adversely affect common stockholders.
• The company may not be able to maintain a current prospectus relating to the shares of common stock issuable upon exercise of the warrants, which would prevent holders from exercising their warrants.

Future Outlook

The company does not intend to pay cash dividends in the foreseeable future, and the payment of any cash dividends will be at the discretion of the Board of Directors.

Management Comments

• The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition.
• The payment of any cash dividends will be within the discretion of our Board of Directors at such time.

Industry Context

This document is a standard disclosure of securities information for a publicly traded company, which is common in the biotechnology industry. The details about the company's capital structure and the terms of its securities are typical for companies listed on the NYSE American Stock Market.

Comparison to Industry Standards

• The structure of BiomX's securities, including common stock, units, and warrants, is similar to that of other early-stage biotechnology companies listed on exchanges like NYSE American.
• The lack of current dividends is common for growth-focused biotech companies that prioritize reinvesting earnings into research and development.
• The terms of the warrants, including the exercise price and expiration date, are typical for warrants issued in connection with public offerings or mergers.
• The anti-takeover provisions are also common for publicly traded companies, especially those in industries with high intellectual property value.
• The staggered board structure is a common corporate governance practice to ensure continuity and stability.

Corporate Governance

Stakeholder Impact

• Shareholders: The document provides information about the company's capital structure and the terms of its securities, which is important for shareholders to understand their rights and potential returns.
• Employees: The document does not directly impact employees, but it provides context for the company's financial position.
• Customers: The document does not directly impact customers.
• Suppliers: The document does not directly impact suppliers.
• Creditors: The document provides information about the company's capital structure, which may be relevant to creditors.

Next Steps

• The company will continue to evaluate its capital requirements and may seek additional funding in the future.
• The company will need to maintain a current prospectus for the shares of common stock issuable upon exercise of the warrants to allow holders to exercise their warrants.

Key Dates

Keywords

common stock, warrants, preferred stock, securities, NYSE American, dividends, redemption, takeover, voting rights, capital stock